RP-HPLC-PDA Method Development, Validation and Stability Studies of the Novel Antineoplastic Drug Combination - Decitabine and Cedazuridine

Abstract

Aim: The aim of our present work was to develop and validate a reverse phase high-performance liquid chromatography (RP-HPLC) method for the simultanious determination of Decitabine (DEC) and Cedazuridine (CED). Methodology: The developed method was further applied to observe the degradation of analytes under the influence of different forced degradation conditions. Analytes were resolved on C18, 250 x 4.6 mm, particle size 5 µm Xterra column, using a mobile phase combination of 0.1% Ortho Phospharic Acid buffer pH 6.5: Methanol (40:60v/v) with flow rate of 1mL/min and injection volume of 10 µL. Quantification was carried out with PDA detector at an isosbestic point of 220 nm with a linear calibration curve in the concentration range of 35-175 μg/mL for DEC and 100-500 μg/mL for CED. Results: Validation of the developed method was performed as per ICH guidelines viz., linearity, accuracy, precision, and robustness. The limits of detection (LOD) and the limits of quantification (LOQ) for CED were found to be 2.69 µg/mL and 8.15 µg/mL respectively. LOD and LOQ for DEC 1.55 µg/mL and 4.68 µg/mL respectively. Moreover, validated method was applied to study the degradation profile of analytes under various stress degradation conditions. Conclusion: The proposed method was found to be sensitive, specific and was successfully applied for the simultaneous estimation of Decitabine (DEC) and Cedazuridine (CED) in bulk drug, and tablets.